Transdermal cannabidiol delivery device
Transdermal delivery devices (TDDs) that provide an easy-to-use method of delivering a consistent, steady dose of cannabidiol (CBD) are shown and described herein. The TDDs include a backing layer coated with a mixture of CBD, a polyisobutene adhesive, and plasticizer. Methods of making and using the same are also described.
1. A transdermal delivery device (TDD) comprising a backing layer and a matrix, wherein the matrix comprises polyisobutylene (PIB) adhesive, an oil, and cannabidiol (CBD), wherein the matrix comprises at least threefold more CBD than a maximum concentration of CBD that dissolves in the oil, wherein the PIB adhesive has an average molecular weight greater than 100 kDa, and wherein the backing layer is inert to the matrix, wherein the oil is a mineral oil with a kinematic viscosity of about 5-30 cSt at 40° C., wherein about 10% (w/w) to about 30% (w/w) of the mass of the matrix is the mineral oil, and wherein the TDD is configured to deliver at least 0.5 mg/cm 2 of CBD across skin of a human subject after adherence of the TDD to the skin for at least 24 hours.
2. The TDD of claim 1 , wherein about 35% (w/w) to about 75% (w/w) of the mass of the matrix is PIB.
3. The TDD of claim 2 , wherein the PIB comprises polymers with a molecular weight from about 800 kDa to about 4 MDa and polymers with a molecular weight from about 25 kDa to about 65 kDa in a ratio of about 1:2 to about 2:1.
4. The TDD of claim 3 , wherein the matrix comprises at least fourfold more CBD than the saturation concentration for CBD in the oil.
5. The TDD of claim 4 , wherein about 16-17% (w/w) of the mass of the matrix is CBD, about 55-66% (w/w) of the mass of the matrix is PIB, and about 17-28% (w/w) of the mass of the matrix is a mineral oil with a kinematic viscosity of about 10.8-13.6 cSt at 40° C.
6. The TDD of claim 1 , further comprising a 1.0-5.0 mm thick polyethylene terephthalate (PET) film coated with a release agent.
7. The TDD of claim 1 , wherein the backing layer is a 1.0-5.0 mm thick low density polyethylene (LDPE) film.
8. The TDD of claim 1 , wherein the TDD is configured to deliver at least 0.65 mg/cm 2 of CBD across skin of a human subject after adherence of the TDD to the skin for at least 24 hours.
9. The TDD of claim 1 , wherein the TDD is configured to deliver at least 50% (w/w) of the CBD through a human subject's skin after adherence of the TDD to the skin for at least 12 hours.
10. The TDD of claim 9 , wherein the TDD is configured to deliver at least 70% (w/w) of the CBD through a human subject's skin after adherence of the TDD to the skin for at least 24 hours.
11. A TDD comprising a backing layer and a matrix comprising PIB adhesive, an oil, and at least 16% (w/w) CBD, wherein the backing layer is inert to the matrix, and wherein the TDD is configured to deliver at least 0.5 mg/cm 2 of CBD across skin of a human subject after adherence of the TDD to the skin for at least 24 hours, wherein the oil is a mineral oil with a kinematic viscosity of about 5-30 cSt at 40° C., and wherein about 15% (w/w) to about 50% (w/w) of the mass of the matrix is mineral oil.
12. The TDD of claim 11 , wherein about 35% (w/w) to about 70% (w/w) of the mass of the matrix is PIB.
13. The TDD of claim 12 , wherein the PIB comprises polymers with a molecular weight from about 800 kDa to about 4 MDa and polymers with a molecular weight from about 25 kDa to about 65 kDa in a ratio of about 1:2 to about 2:1.
14. The TDD of claim 13 , wherein about 15-25% (w/w) of the matrix is CBD.
15. The TDD of claim 14 , wherein about 55-66% (w/w) of the mass of the matrix is PIB, and about 17-28% (w/w) of the mass of the matrix is mineral oil.
16. The TDD of claim 15 , further comprising a 1.0-5.0 mm thick PET film coated with a release agent.
17. The TDD of claim 11 , wherein the backing layer is a 1.0-5.0 mm thick LDPE film.
18. The TDD of claim 11 , wherein the TDD is configured to deliver at least 0.65 mg/cm 2 of CBD across skin of a human subject after adherence of the TDD to the skin for at least 24 hours.
19. The TDD of claim 11 , wherein the TDD is configured to deliver at least 50% (w/w) of the CBD through a human subject's skin after adherence of the TDD to the skin for at least 12 hours.
20. The TDD of claim 19 , wherein the TDD is configured to deliver at least 70% (w/w) of the CBD through a human subject's skin after adherence of the TDD to the skin for at least 24 hours.
21. A method of delivering CBD to a subject, the method comprising adhering the TDD of claim 1 to skin of the subject for at least 8 hours.
22. The method of claim 21 , comprising delivering CBD at a transdermal flux of at least 0.6 mg/cm 2 per 24 hours to the subject.
23. A method of delivering CBD to a subject, the method comprising adhering the TDD of claim 11 to skin of the subject for at least 8 hours.
24. The method of claim 23 , comprising delivering CBD at a transdermal flux of at least 0.6 mg/cm 2 per 24 hours to the subject.
25. A method of treating a subject suffering from seizures, comprising adhering the TDD of claim 1 to skin of the subject.
26. A method of enhancing an analgesic effect in a subject in need of pain relief, the method comprising adhering the TDD of claim 1 to skin of the subject, wherein the subject has been, is, or will be administered an analgesic agent.